OliX PharmaceuticalsInc Total Liabilities
OliX PharmaceuticalsInc total liabilities. Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has total liabilities worth ₩36.64 Billion KRW (≈ $24.83 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of OliX PharmaceuticalsInc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of OliX PharmaceuticalsInc (2016–2025)
Total liabilities of OliX PharmaceuticalsInc from 2016 to 2025. This chart illustrates how OliX PharmaceuticalsInc's total liabilities have evolved over time, based on quarterly financial data. Check OliX PharmaceuticalsInc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
OliX PharmaceuticalsInc Competitors by Total Liabilities
The table below lists competitors of OliX PharmaceuticalsInc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Eazytec Co Ltd
SHG:688258
|
China | CN¥697.80 Million |
|
Vanchip (Tianjin) Technology Co. Ltd. A
SHG:688153
|
China | CN¥461.04 Million |
|
Guangdong Tapai Group Co Ltd
SHE:002233
|
China | CN¥1.22 Billion |
|
Taiwan Fertilizer Co Ltd
TW:1722
|
Taiwan | NT$30.21 Billion |
|
ROMANDE ENERGIE SA
SW:REHN
|
Switzerland | CHF701.99 Million |
|
Hong Leong Industries Bhd
KLSE:3301
|
Malaysia | RM725.26 Million |
|
REX American Resources Corporation
NYSE:REX
|
USA | $83.92 Million |
|
Henan Zhongyuan Expressway Co Ltd
SHG:600020
|
China | CN¥41.36 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down OliX PharmaceuticalsInc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OliX PharmaceuticalsInc (226950) total assets.
Liquidity & Leverage Metrics
OliX PharmaceuticalsInc Total Liabilities Ratios Explained
OliX PharmaceuticalsInc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OliX PharmaceuticalsInc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OliX PharmaceuticalsInc (2016–2025)
The table below shows the annual total liabilities of OliX PharmaceuticalsInc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩45.29 Billion ≈ $30.69 Million |
-15.19% |
| 2024-12-31 | ₩53.40 Billion ≈ $36.19 Million |
+1.74% |
| 2023-12-31 | ₩52.49 Billion ≈ $35.57 Million |
-21.36% |
| 2022-12-31 | ₩66.74 Billion ≈ $45.23 Million |
-2.06% |
| 2021-12-31 | ₩68.15 Billion ≈ $46.18 Million |
+104.71% |
| 2020-12-31 | ₩33.29 Billion ≈ $22.56 Million |
+876.59% |
| 2019-12-31 | ₩3.41 Billion ≈ $2.31 Million |
+387.74% |
| 2018-12-31 | ₩698.94 Million ≈ $473.66K |
-76.42% |
| 2017-12-31 | ₩2.96 Billion ≈ $2.01 Million |
+14.35% |
| 2016-12-31 | ₩2.59 Billion ≈ $1.76 Million |
-- |
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more